Treatment of severe heart failure using myocardial transplantation from iPS cells.

According to Heartseed, clinical trials on 10 patients with severe heart failure showed that myocardial transplantation using iPS cells improved heart function and clinical symptoms.

A clinical study by the startup Heartseed, affiliated with Keio University (Tokyo, Japan), has just recorded promising results in treating severe heart failure using transplantation of myocardial cell spheres created from induced pluripotent stem cells (iPS).

iPS cells are mature cells that have been modified to revert to a "pluripotent" stem cell state, capable of differentiating into many different cell types.

According to Heartseed, clinical trials on 10 patients with severe heart failure showed that the transplant method improved heart function and clinical symptoms, and no serious safety issues were reported.

In the study, patients with ischemic heart disease, including myocardial infarction and angina, were divided into two groups to assess the effects of dosage. The low-dose group received 50 million myocardial cells, while the high-dose group received 150 million cells.

Follow-up results showed that, after one year, approximately 80% of patients in the low-dose group had improved or maintained cardiac function at a higher level than before transplantation.

Notably, one patient increased their walking distance in 6 minutes from 150m to 500m. In the high-dose group, all five patients showed an improvement in cardiac function after 6 months of transplantation.

Notably, the study found no serious risks such as tumor formation or cardiac arrhythmias in either group, thus reinforcing the safety of this new treatment method.

Japanese scientists expect that the transplanted myocardial cell spheres will continue to grow within the heart muscle, contributing to the restoration and improvement of the heart's pumping capacity.

Heartseed is currently finalizing its data analysis and expediting the procedures for obtaining product manufacturing and distribution approvals, expected by the end of 2026.

(VNA/Vietnam+)

Source: https://www.vietnamplus.vn/dieu-tri-benh-suy-tim-nang-bang-phuong-phap-cay-ghep-co-tim-tu-te-bao-ips-post1083149.vnp